So-Young's Pivot to a Profitable Aesthetic Clinic Model: AI and Co-Creation as Catalysts
Q2 2026 marks a clear shift from platform to integrated clinic chain, with 130% revenue growth in its aesthetic treatment business and a sharply defined path to group profitability.
SY · Earnings Call · 2026-08-31
A Strategic Reinvention: From Online Platform to Clinic Pioneer
So-Young International Inc. delivered a Q2 2026 that crystallizes its transformation from an online marketplace into a scale-driven aesthetic clinic operator. The company's aesthetic treatment business generated RMB 331.4 million in revenue, up ~130% year-over-year, marking its 10th straight quarter of triple-digit growth. Group revenue hit an all-time high of RMB 505.2 million, and net loss narrowed by 37% to RMB 22.7 million. The company now runs 65 clinics across 18 cities, with 47 centers profitable and 51 generating positive operating cash flow. CEO Xing Jin described the quarter succinctly: “The dual engine approach delivered clear results this quarter.” — Mona Qiao, Host / Investor Relations · 2026-08-31 This pivot is not merely incremental; it represents a structural change in how So-Young captures value. Historically a provider of information and reservation services, the company is now investing heavily in its own branded clinics. The legacy information and reservation services segment was down 35%, underscoring a deliberate reallocation of resources. Management reinforced its focus on high-growth, profitable operations. The shift is echoed in the company's keyword momentum: high growth and clinic business now dominate the narrative, replacing earlier themes like “reservation services” and “marketing expense.” In a prior call (May 2026), management expressed unwavering conviction in the light medical aesthetic sector: “We remain bullish on [ light ] medical aesthetic in China... Cstructural opportunities remain.” — Mona Qiao, Host / Interpreter · 2026-05-22 That conviction is now tangible in the operating metrics. Same-store sales growth jumped to 52% from just 14% a year earlier, and the average revenue per mature center continues to rise. The company is proving that its “fast-casual” aesthetic model—smaller spaces, standardized treatments, higher frequency—can scale profitably.AI-Enabled Operations and Product Co-Creation
Beyond its physical footprint, So-Young is embedding AI across its operations to standardize medical delivery and deepen upstream collaboration. “In Q4 this year, we will roll out our first generation of fully intelligent centers, initiating widespread AI deployment across our network.” — Mona Qiao, Host / Investor Relations · 2026-08-31 The company is building a real-world database and clinical AI infrastructure to support physician training, quality control, and personalized treatment recommendations. This AI-first approach is also transforming its supply chain relationships—moving from transactional buyer-vendor interactions to joint product co-creation. The collaboration with Jinbo Biopharmaceutical on Miracle Collagen is a prime example: over 66,000 units have been sold, and management plans to extend this co-development model to more domestic and international partners. As one analyst noted, this is a departure from the industry norm: “Downstream clinics are often just distribution channels; So-Young is turning its network into innovation infrastructure.” “By leveraging real-world consumer demand, hands-on experience and treatment outcomes to deliver R&D, we aim to accelerate technology innovation and product integration.” — Mona Qiao, Host / Investor Relations · 2026-08-31 The integration of AI integration into both clinical delivery and product innovation is a fresh and company-unique theme. It is a differentiator that could be the key to sustainable margins. The company’s earlier calls (e.g., May 2026) emphasized physician-led consultations and standardized training, but today’s emphasis on real-world data loops to inform procurement and inventory is a new level of sophistication. Management is confident this will lower acquisition costs and improve gross margins.Profitability Inflection and the Road Ahead
What stands out most in the current call is the deliberate move toward group profitability. CFO Shannon Shen articulated a clear-lever strategy:That focus translates into raising the bed capacity utilization benchmark by 50% (from 10 to 15 treatments per day per bed), improving workflow efficiency, and scaling back loss-making peripheral businesses. Gross margin for the aesthetic treatment business improved 3.8 percentage points year-over-year to 28.1%, despite opening 11 new centers in the quarter—a testament to the model’s operating leverage. Looking ahead, management guided Q3 aesthetic treatment revenue to RMB 352–362 million (91.7%–97.2% YoY growth). They project continued gross margin expansion into H2, driven by procurement scale, a strong product pipeline (including new PLLA variants and collagen products), and the AI-driven efficiency gains. The company is on the cusp of breaking even at the clinic level, and the tone on the call suggests they see that as imminent. This transformation is not without residual drag: the legacy platform business continues to decline, and the company is deliberately pruning other loss-makers. Yet the operational evidence—10 consecutive quarters of triple-digit growth, improving margins, and a clear strategic narrative—points to a genuine inflection point. So-Young is no longer a “platform” story; it is a technology-enabled provider of standardized medical aesthetic care, and the market has yet to fully re-rate it. This is a classic company-unique strategic pivot, backed by strong fundamental improvements and a distinctive AI-integrated approach.To sum up, our core lever for loss reduction this year, in one word, it is focus.